Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

es' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether the results of the Phase IIb trial are predictive of results in subsequent trials of tezampanel, whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of its drug candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of its drug candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of its drug candidates will support a filing for marketing approval, will be approved by the regulatory authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's drug development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical trials will be reported within the anticipated timeframe, that tezampanel will successfully treat migraine pain, that NGX267 will successfully treat the symptoms of cognitive impairment associated with schizophrenia, that NGX267 will successfully treat xerostomia or that TorreyPines will be able to complete the necessary development work and receive regulatory approval for tezampanel or NGX267. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31,2006 and TorreyPines other SEC reports. The forward-looking statements are based on current information that is lik
'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... (PRWEB) September 30, 2014 Whitehouse ... been chosen by the Parenteral Drug Association (PDA) ... and 19, 2014) on container closure integrity testing. This ... integrity test methods and philosophies detailed in the recently ... Evaluation. The course will span container closure ...
(Date:9/30/2014)... Pittsburgh PA (PRWEB) September 30, 2014 ... Nurses ( IACRN), a non-profit organization based ... Clinical Research Excellence and Safety (ACRES), a ... of a strategic alliance agreement, setting the stage ... is to enhance clinical research quality and safety ...
(Date:9/29/2014)... diagnostics today, with imaging techniques like MRI (magnetic ... (nuclear magnetic resonance) increasing steeply over the last ... and quality still limit these techniques because of ... hyperpolarization, which involves injecting the patient with substances ... distribution and fate of specific molecules in the ...
(Date:9/29/2014)... VIRGINIA BEACH, Va. , Sept. 29, 2014 ... scientists from the fields of cartilage repair, regeneration, ... as attendees from around the world gathered to ... 2014 LifeNet Health Institute of Regenerative Medicine symposium, ... Future Direction . Topics included Orthopedic Biosurgery, Minced ...
Breaking Biology Technology:Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 3Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 4IACRN and ACRES to Support Clinical Research Nurses 2IACRN and ACRES to Support Clinical Research Nurses 3A safer approach for diagnostic medical imaging 2A safer approach for diagnostic medical imaging 3World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3
... and we are emerging into the second week of March, its ... this will be a good or bad year for biotechnology. In ... already taken place that impact the land of U.S. biotech. Witness ... weeks has approved not one but two new cancer drugs coming ...
... 34 communities across Wisconsin are competing in Phase 2 of ... ,The contestants were selected from a field of 330 ... Technology Council. WTC is producing the contest in conjunction with ... statewide affiliates. , ,We are very honored to be ...
... It shouldnt come as a surprise that Wisconsins high-tech ... was true across the United States as the shock waves ... of Sept. 11, 2001, battered the economy. The tech indicators ... time, the latest economic tracking report by Competitive Wisconsin Inc. ...
Cached Biology Technology:Biotech 2004: Cautious optimism 2Biotech 2004: Cautious optimism 3Seeds for high-tech economy are being planted, but growth will take time 2Seeds for high-tech economy are being planted, but growth will take time 3
(Date:9/30/2014)... , Sept. 30, 2014  Spectra ... solutions for the biotech and power generation ... new RECONN Bioprocess Manager, an easy-to-use and ... geared towards bioprocess development laboratories. ... disparate bioreactor and analyzer systems. Accessing and ...
(Date:9/30/2014)... 30, 2014) People who suffer from asthma may ... control their asthma besides properly taking medications and avoiding ... in the Annals of Allergy, Asthma and Immunology ... Allergy, Asthma and Immunology (ACAAI), asthma sufferers can learn ... The woman described in the Annals article improved her ...
(Date:9/29/2014)... Clostridium ramosum , coupled with a high-fat diet, may ... week in mBio , the online open-access journal of ... from the German Institute of Human Nutrition Potsdam-Rehbruecke in Nuthetal ... ramosum gained weight when fed a high-fat diet. Mice ... obese even when consuming a high-fat diet, and mice that ...
Breaking Biology News(10 mins):Spectra Automation Introduces RECONN Bioprocess Manager 2Asthma symptoms kicking up? Check your exposure to air pollution 2Gut bacteria promote obesity in mice 2
... H9N2 virus. , ... , , , ... , , ... , , , College Park, Md. - A new study by University ...
... at Scripps Institution of Oceanography at UC San Diego have ... blue waters of Lake Tahoe one earthquake at a time. ... more comprehensive analysis of earthquake activity in the Lake Tahoe ... 3,000 years in the basin, and that the largest fault ...
... April 29 Differing biological response to infection between ... older men who are hospitalized with community-acquired pneumonia (CAP). ... Medicine journal, may have important implications for understanding ... that men with CAP were less likely to survive ...
Cached Biology News:Avian flu research sheds light on swine flu outbreak 2Avian flu research sheds light on swine flu outbreak 3Avian flu research sheds light on swine flu outbreak 4Avian flu research sheds light on swine flu outbreak 5Scripps studies offer new picture of Lake Tahoe's earthquake potential 2Older men more likely than women to die after pneumonia 2Older men more likely than women to die after pneumonia 3
Sheep Serum US Origin...
... and flexibility press-to-seal silicone isolators can be ... researcher. They are available either pre-cut to ... that can be easily trimmed to prepare ... non-cytotoxic and can be used to isolate ...
2,4-Dinitrophenyl hapten is conjugated to Human Serum Albumin (HSA) protein through lysine....
IC50: 3 ng/ml · Limit of detection: 0.5 ng/ml...
Biology Products: